Noxopharm Limited (ASX: NOX) is pleased to announce that it has received $3.71M cash rebate as part of the Federal Government R&D Tax Incentive Scheme. Greg van Wyk, Noxopharm Chief Executive Officer, said, ‘The support we receive from the Australian Government, by way of the R&D rebate scheme, is a key factor in enabling us to conduct high quality research with Australian scientific partners and be able to select partners in other jurisdictions. We are grateful for this support.’
For more information, download the attached PDF.
Download this document
